Outset Medical (NASDAQ:OM) Price Target Lowered to $15.00 at BTIG Research

Outset Medical (NASDAQ:OM) had its target price cut by BTIG Research from $17.00 to $15.00 in a research note published on Thursday morning, Marketbeat Ratings reports. They currently have a buy rating on the stock.

Several other research firms have also weighed in on OM. Royal Bank Of Canada restated a “sector perform” rating and set a $7.00 price objective on shares of Outset Medical in a report on Wednesday, December 17th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Outset Medical in a report on Monday, December 29th. Wall Street Zen downgraded Outset Medical from a “hold” rating to a “sell” rating in a research report on Sunday, February 8th. Finally, Stifel Nicolaus dropped their price target on Outset Medical from $14.00 to $8.00 and set a “buy” rating for the company in a research note on Wednesday, January 7th. One equities research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $10.00.

Outset Medical Stock Down 16.3%

OM stock opened at $3.80 on Thursday. The company has a quick ratio of 5.77, a current ratio of 7.09 and a debt-to-equity ratio of 0.69. The firm has a market capitalization of $68.97 million, a PE ratio of -0.56 and a beta of 2.08. The stock’s 50 day moving average is $4.44 and its 200-day moving average is $9.52. Outset Medical has a twelve month low of $3.10 and a twelve month high of $21.98.

Insider Activity

In other Outset Medical news, General Counsel John L. Brottem sold 9,314 shares of the business’s stock in a transaction dated Tuesday, January 20th. The stock was sold at an average price of $5.12, for a total transaction of $47,687.68. Following the completion of the sale, the general counsel directly owned 36,957 shares in the company, valued at $189,219.84. The trade was a 20.13% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Leslie Trigg sold 11,794 shares of the stock in a transaction that occurred on Tuesday, January 20th. The stock was sold at an average price of $5.12, for a total transaction of $60,385.28. Following the completion of the transaction, the chief executive officer owned 107,823 shares in the company, valued at $552,053.76. The trade was a 9.86% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 35,989 shares of company stock worth $180,073 over the last three months. 2.40% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Outset Medical

A number of institutional investors have recently bought and sold shares of OM. HRT Financial LP purchased a new stake in shares of Outset Medical during the fourth quarter worth about $58,000. Aristides Capital LLC purchased a new position in Outset Medical in the fourth quarter worth about $177,000. Paradigm Capital Management Inc. NY bought a new stake in Outset Medical during the fourth quarter worth approximately $148,000. Renaissance Technologies LLC raised its holdings in Outset Medical by 11.7% during the 4th quarter. Renaissance Technologies LLC now owns 45,205 shares of the company’s stock valued at $168,000 after buying an additional 4,745 shares during the period. Finally, Dimensional Fund Advisors LP increased its position in Outset Medical by 372.2% during the fourth quarter. Dimensional Fund Advisors LP now owns 158,352 shares of the company’s stock valued at $587,000 after acquiring an additional 124,817 shares during the last quarter.

Trending Headlines about Outset Medical

Here are the key news stories impacting Outset Medical this week:

• Positive Sentiment: Analysts kept buy ratings despite lowering price targets — BTIG trimmed its target to $15 but maintained a “buy” rating, and Stifel also lowered its target while keeping a buy view, signaling continued analyst confidence in recovery potential. BTIG/The Fly coverage
• Neutral Sentiment: FY2026 revenue guidance set at $125M–$130M, close to the $127.3M consensus (slightly below midpoint), so guidance is not a dramatic miss but provides limited upside visibility; EPS guidance was not clearly specified in public notes. Company press release
• Neutral Sentiment: Earnings call transcript available for color on commercial progress and cost initiatives; useful for investors wanting management detail on sales cadence and margin timing. Earnings call transcript
• Negative Sentiment: Q4 EPS missed materially — reported loss of ($0.84) vs. consensus ($0.45), and the company showed a deeply negative net margin and ROE, prompting near-term profitability concerns. Earnings press release / financials
• Negative Sentiment: Analysts trimmed price targets (BTIG from $17 to $15; Stifel to $8), which reduces implied upside and may cap near-term momentum even though ratings stayed at buy. BTIG price target note Stifel coverage
• Negative Sentiment: Technically vulnerable: the stock is trading well below its 50- and 200-day moving averages and near its 52‑week low, increasing downside risk for momentum-focused traders. Press coverage of stock reaction
• Positive Sentiment: Balance sheet liquidity appears healthy (strong quick and current ratios), which gives management room to execute on commercialization and cost programs without immediate financing pressure. (See company filings for details.)

About Outset Medical

Outset Medical is a medical technology company specializing in innovations for renal care. The company’s flagship offering, the Tablo Hemodialysis System, is designed to streamline and simplify dialysis treatment across acute and outpatient settings. By integrating water purification, dialysate production, and treatment monitoring into a single device, Tablo aims to reduce the complexity and logistical burden traditionally associated with hemodialysis therapy.

Tablo’s modular design allows for rapid setup and flexible deployment in hospitals, clinics, long‐term care facilities and emergency response scenarios.